Extended Data Fig. 5: Immunohistochemical analysis of immune cell infiltration of pre-immune checkpoint blockade (ICB) and post-ICB tumors.
From: Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
a, and b, Intra-patient comparison of paired pre- (a) and post-ICB tumors (b). CD8 tumor infiltrating lymphocytes (CD8 TILS) in the non-ICB exposed urothelial cancer and the post-ICB exposure cutaneous squamous cell carcinoma. HPF: High Power Field. c, Interpatient comparisons of CD8 TILS, programmed cell death 1 protein (PD1) positive TILS and programmed cell death ligand 1 (PDL1) combined positive score (CPS) in tumors arising prior to ICB exposure (N = 8), tumors arising whilst patients were on ICB (N = 5) and tumors arising post completion of ICB (N = 2). Mean and standard deviation (SEM) are represented and compared using ordinary one way ANOVA test corrected for multiple comparisons.*: P ≤ 0.05 and P > 0.01, ns: non significant. Stains with the relevant antibodies, CD8 antibody (clone C8/144B, Catalog # sc-53212, diluted 1:100, Dako), PD-1 (clone NAT105, Catalog # 760-4895, ready to use, Cell Marque), and PD-L1 (cloneE1L3N, Catalog # 13684 S, diluted 1:100, Cell Signaling) were run on each chosen study tissue block once. All antibodies and staining protocols are validated and optimized to current standards.
